Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid

Tuberculosis

Volumn 84, Issue 6, 2004, Pages 365-373

  Nix, David E ^a   Adam, Rodney D ^b   Auclair, Barbara ^c   Krueger, Todd S ^a   Godo, Paul G ^c   Peloquin, Charles A ^c,d,e  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Bioavaibility; Clofazimine; Food effect; Pharmacokinetics

Indexed keywords

ALUMINUM HYDROXIDE; AMINOSALICYLIC ACID; CLOFAZIMINE; CYCLOSERINE; ETHIONAMIDE; FAT; MAGNESIUM HYDROXIDE; MYLANTA; PYRIDOXINE; WATER;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG SAFETY; FOOD; HUMAN; MEAL; NORMAL HUMAN; ORANGE JUICE; POPULATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADMINISTRATION, ORAL; ADULT; ANTACIDS; ANTITUBERCULAR AGENTS; BEVERAGES; BIOLOGICAL AVAILABILITY; CITRUS SINENSIS; CLOFAZIMINE; CROSS-OVER STUDIES; CYCLOSERINE; DIETARY FATS; DRUG COMBINATIONS; DRUG INTERACTIONS; ETHIONAMIDE; FOOD; FOOD-DRUG INTERACTIONS; HUMANS; LEPROSTATIC AGENTS; P-AMINOSALICYLIC ACID; PYRIDOXINE;

EID: 7544247898     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tube.2004.04.001     Document Type: Article

References (12)

1. Bass J.B. Jr., Farer L.S., Hopewell P.C., O'Brien R., Jacobs R.F., Ruben F., et al. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. Am J Respir Crit Care Med. 149(5):1994;1359-1374
2. Reddy V.M., Nadadhur G., Daneluzzi D., O'Sullivan J.F., Gangadharam P.R. Antituberculosis activities of clofazimine and its new analogs B4154 and B4157. Antimicrob Agents Chemother. 40(3):1996;633-636
3. O'Connor R., O'Sullivan J.F., O'Kennedy R. The pharmacology, metabolism, and chemistry of clofazimine. Drug Metab Rev. 27(4):1995;591-614
4. Schaad-Lanyi Z., Dieterle W., Dubois J.P., Theobald W., Vischer W. Pharmacokinetics of clofazimine in healthy volunteers. Int J Lepr Other Mycobact Dis. 55(1):1987;9-15
5. Levy L. Pharmacologic studies of clofazimine. Am J Trop Med Hyg. 23(6):1974;1097-1109
6. Peloquin C.A., Zhu M., Adam R.D., Singleton M.D., Nix D.E. Pharmacokinetics of para-aminosalicylic acid granules under four dosing conditions. Ann Pharmacother. 35(11):2001;1332-1338
7. Zhu M., Nix D.E., Adam R.D., Childs J.M., Peloquin C.A. Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids. Pharmacotherapy. 21(8):2001;891-897
8. Auclair B., Nix D.E., Adam R.D., James G.T., Peloquin C.A. Pharmacokinetics of ethionamide administered under fasting conditions or with orange juice, food, or antacids. Antimicrob Agents Chemother. 45(3):2001;810-814
9. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron. 16(1):1976;31-41
10. Devine B.J. Gentamicin therapy. Drug Intell Clin Pharm. 8(9):1974;650-655
11. Jonsson E.N., Karlsson M.O. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 58(1):1999;51-64
12. Anon Lamprene product information. 1998;Novartis Pharmaceuticals Corp, East Hanover, NJ